Anti-NGF antibodies and their use
The present disclosure encompasses NGF binding proteins, specifically to antibodies that are chimeric, CDR grafted and canonized antibodies, and methods of making and uses thereof. The antibodies, or antibody portions, of the disclosure are useful for detecting NGF and for inhibiting NGF activity, e.g., in a mammal subject suffering from a disorder in which NGF activity is detrimental.
1. An isolated anti-NGF antibody that specifically binds to Nerve Growth Factor (NGF) and inhibits the binding of NGF to the TrkA receptor comprising:
a) a variable heavy chain (VH) region comprising:
i) CDR1 comprising SEQ ID NO. 61,
ii) CDR2 comprising SEQ ID NO. 62; and
iii) CDR3 comprising SEQ ID NO. 63; and
b) a variable light chain (VL) region comprising:
i) CDR1 comprising SEQ ID NO. 64,
ii) CDR2 comprising SEQ ID NO. 65; and
iii) CDR3 comprising SEQ ID NO. 66; and
wherein the antibody is a chimeric antibody.
2. An isolated anti-NGF antibody that specifically binds to Nerve Growth Factor (NGF) and inhibits the binding of NGF to the TrkA receptor comprising:
a) a variable heavy chain (VH) region comprising:
i) CDR1 comprising SEQ ID NO. 61,
ii) CDR2 comprising SEQ ID NO. 62; and
iii) CDR3 comprising SEQ ID NO. 63; and
b) a variable light chain (VL) region comprising:
i) CDR1 comprising SEQ ID NO. 64,
ii) CDR2 comprising SEQ ID NO. 65; and
iii) CDR3 comprising SEQ ID NO. 66; and
wherein the antibody is a caninized antibody.
3. An isolated anti-NGF antibody that specifically binds to Nerve Growth Factor (NGF) and inhibits the binding of NGF to the TrkA receptor comprising:
a) a variable heavy chain (VH) region comprising:
i) CDR1 comprising SEQ ID NO. 61,
ii) CDR2 comprising SEQ ID NO. 62; and
iii) CDR3 comprising SEQ ID NO. 63; and
b) a variable light chain (VL) region comprising:
i) CDR1 comprising SEQ ID NO. 64,
ii) CDR2 comprising SEQ ID NO. 65; and
iii) CDR3 comprising SEQ ID NO. 66; and
wherein the antibody is a humanized antibody.
4. A pharmaceutical composition comprising a therapeutically effective amount of any one of the antibodies of claims 1 - 3 and a pharmaceutically acceptable carrier, diluent or excipient.